COCO — Q3 2026 Financial Report Analysis

Sales up 34% with Copra's first ten weeks, but the gross margin only held flat, and management now guides Q4 margin down to about 33%

The Vita Coco Company sells packaged coconut water under its Vita Coco brand (the top-selling coconut water in the U.S.), makes coconut water and coconut oil for retailers' own store brands ("private label"), and, since July 22, 2026, owns Copra, a Thai coconut water maker with its own factory. In the quarter ended September 30, 2026, net sales rose 33.7% to $243.8 million, net income rose 45.9% to $35.0 million, and diluted earnings per share (EPS) were $0.58 versus $0.40 a year earlier.

Unlike last quarter, there is no one-time refund in these numbers: the $15.6 million tariff refund was booked entirely in Q2. About 16 points of the 34% sales growth came from Copra, which Vita Coco did not own a year ago. The rest, 17.8% "organic" growth (growth from the business it already had), came mostly from shipping more product rather than charging more: Vita Coco coconut water cases rose 15.8%, while net prices in the Americas fell.

Key figures

Operating margin is the share of sales left after paying for the product and running the business (selling, general and administrative costs, or SG&A), before interest, currency items and tax. Adjusted EBITDA is the company's own profit measure: earnings before interest, tax, depreciation and amortization, also excluding stock-based pay, currency and hedging gains and losses, and (new this quarter) Copra deal costs. A "case" is a case equivalent: 12 bottles of 330ml.

Over the first nine months, net sales were $639.7 million (+32.7%), net income $114.9 million (+74.7%) and diluted EPS $1.89 versus $1.10. The nine-month figures still include Q2's $15.6 million tariff refund, which the company says added 2.4 points to year-to-date gross margin.

Where the growth came from

The brand is growing fastest in Europe. International Vita Coco sales rose 56.6% on 50.5% more cases; the 10-Q credits "strong volume growth in Europe, particularly in Germany and the U.K., coupled with favorable pricing." Europe is still a small base ($34.4 million against $143.3 million in the Americas), but it supplied more than half of the brand's dollar growth this quarter.

In the Americas, the brand grew on volume while prices slipped. Sales rose 8.2% on 8.5% more cases, and the 10-Q says the gain was "partly offset by net lower pricing" (net pricing is the list price after promotional discounts). That is a change from the first half, when Americas brand growth relied heavily on pricing. It also matters for margins: the 10-Q names lower net pricing as one of the things that kept gross margin flat.

Private label more than doubled, partly through Copra. Most of Copra's sales are store-brand coconut water, which is booked in Private Label; Copra's own branded coconut water and its sales of coconut by-products ("commodity sales") go in Other. The 10-Q says Americas private label growth reflects "both the contribution from the Copra acquisition and strong organic growth from new and regained distribution and increased velocities" (velocity is how fast product sells once it is on the shelf), but does not split the two. Private label is now 23.3% of total sales, up from 12.3% a year ago, which is the "adverse product mix" management cites in its margin guidance: store-brand cases earn less than branded ones.

What the headline numbers hide

This quarter is clean of last quarter's one-off, but the year-ago comparison is not. The $15.6 million IEEPA tariff refund that inflated Q2 profit does not touch Q3. But Q3 2025 still carried tariffs on imported coconut water, before the U.S. exempted most of the company's coconut water products in November 2025. So the margin line compares a quarter with tariffs against one with "minimal tariffs." The 10-Q lists that "non-recurrence" of tariffs as the main reason gross margin rose, "partially offset by lower net pricing, higher domestic logistics costs, and the dilutive impact of Copra." In other words, without the tariff relief, gross margin would have fallen year on year; the filing does not say by how much.

Operating profit grew faster than net income, for three reasons below the operating line. Operating income rose 62.8%, helped by SG&A rising more slowly (+15.9%) than sales (+33.7%). Net income rose less, 45.9%, because:

• Currency hedges swung from a $2.4 million gain to a $2.1 million unrealized loss (the 10-Q cites Brazilian real and Thai baht contracts), which, with a smaller currency loss, turned $2.8 million of other income last year into a $1.8 million expense.
• Interest income fell to $1.2 million from $1.8 million because Copra's $139 million cash cost drained the cash pile.
• Diluted shares rose 1.6% to 60.8 million (see below).

A lower tax rate (19.7% versus 21.8%) helped slightly; at last year's rate, net income would have been about $0.9 million lower (our estimate).

Copra deal costs and new amortization hold down this quarter's reported profit. SG&A includes $3.2 million of acquisition costs (lawyers, advisers, insurance) and $1.0 million of amortization, the accounting charge that spreads the value of Copra's customer relationships and trade names over 12 to 20 years. The deal costs won't recur; the amortization will, at a slightly higher rate in a full quarter. Excluding the $3.2 million of deal costs, SG&A grew about 8%. After tax, those deal costs cost roughly $0.04 of EPS (our estimate at the quarter's 19.7% tax rate), so underlying EPS was about $0.62.

Cash generation is strong. Operating cash flow for the nine months was $151.9 million against $114.9 million of net income, up from $51.1 million a year earlier. For Q3 alone it was about $55 million (nine months minus the first half's $96.5 million) against $35.0 million of net income. Part of that came from inventory: total inventory was $111.3 million, flat with December, even though Copra brought in $33.3 million of its own, so the existing business ran its stocks down by roughly that amount. Receivables (money owed by customers) rose 58% since December to $128.7 million, faster than sales, but they fell from $132.3 million at the end of June, so this looks like normal seasonal timing plus Copra's own customers ($5.2 million at closing), not a collection problem.

Buybacks did not lift EPS. Vita Coco spent $62.4 million on share repurchases in the nine months, about $42 million of it in Q3, and another $7.6 million in October, leaving $10.9 million under the current program. Diluted shares still rose 1.6% year on year, because it also issued 467,071 shares to Copra's owners and stock awards keep adding shares. EPS growth came from the business, not from a shrinking share count.

Copra adds a new kind of liability. Beyond the $147.6 million cash and $35.0 million of shares paid at closing, Vita Coco owes Copra's sellers an earnout of $45–100 million in 2029 based on Copra's 2028 gross profit, carried at an estimated $55.1 million. That figure will be re-estimated every quarter and any change goes through net income, so it can add noise to future GAAP profits in either direction. Copra also brought $102.4 million of goodwill and $108.1 million of intangible assets onto a balance sheet that had $7.8 million of goodwill in December. The company still has no debt and $152.0 million of cash, down from $278.6 million at the end of June.

Did last quarter's read hold up?

Our Q2 report said the guidance implied second-half gross margin of roughly 35% and second-half Adjusted EBITDA of about $48–55 million. Q3 came in better than that on its own: 38.0% gross margin and $53.2 million of Adjusted EBITDA, nearly the whole implied half-year amount in one quarter. The margin squeeze has not gone away, it has moved into Q4: management now guides Q4 gross margin to about 33%, so the second half should average around 36%. Our Q2 report also asked whether Americas brand volume would pick up once a promotion-timing distortion dropped out: it did, modestly, from +6.6% in Q2 to +8.5%. And we flagged that the Q2 10-Q gave no figures for Copra: we now know it added about 16 points of sales growth and that the company calls it "dilutive" to gross margin, though Copra's profit is still not disclosed.

Takeaway: Demand is not the issue: organic sales grew 17.8% and branded coconut water volume 15.8%, and management raised its sales and profit guidance for the second quarter in a row. The pressure is on cost. A flat 38% gross margin in a quarter that got a tariff tailwind, plus a guided ~33% in Q4, means product, freight and trucking costs are rising faster than prices, and the company says it won't raise prices until early 2027.

Outlook

Management raised its 2026 guidance:

The arithmetic: nine-month sales of $639.7 million and Adjusted EBITDA of $159.1 million leave about $170–180 million of Q4 sales and only about $11–16 million of Q4 Adjusted EBITDA, against $53.2 million in Q3. Part of that is seasonal (coconut water sells less in winter), but the release ties the 33% Q4 gross margin to "increases in cost of goods and no offsetting price actions expected until early 2027." CEO Martin Roper said organic growth "exceed[ed] our expectations" and "consumer demand is very healthy." The 10-Q's risk factors add that the conflict involving Iran has raised fuel and energy costs for its suppliers and disrupted shipping through the Strait of Hormuz.

Our view: the volume story is intact in both regions, and the company is funding growth from its own cash with no debt. The things to watch in the next report (the Q4/full-year 2026 results, likely in late February 2027) are (1) whether Q4 gross margin lands near the guided 33% or below it; (2) the size and timing of the early-2027 price increases, and whether Americas volume holds up after them, given that net pricing was already slipping this quarter; (3) a first full quarter of Copra, including whether its margin improves under Vita Coco's ownership and any change in the estimated earnout; and (4) any new U.S. tariffs, which the 10-Q says the administration has announced it intends to impose under other legal authorities. The organic growth figure, Copra's contribution and the guidance come from the company's earnings release (Exhibit 99.1); all other figures are from the 10-Q.